Evaluation of the bioequivalence of two transdermal fentanyl systems following single and repeat applications

Current Medical Research and Opinion

Volumn 21, Issue 12, 2005, Pages 1961-1968

  Sathyan, Gayatri ^a   Guo, Cindy ^a   Sivakumar, Krishna ^a   Gidwani, Shalini ^a   Gupta, Suneel ^a  

^a ALZA CORPORATION   (United States)

Author keywords

Bioequivalence; Fentanyl; Transdermal

Indexed keywords

FENTANYL;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MEGADOSE; DRUG TOLERABILITY; EDEMA; ERYTHEMA; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MEDICAL ASSESSMENT; NAUSEA; NORMAL HUMAN; OBSERVER VARIATION; PAPULE; PATIENT ATTITUDE; PRURITUS; PUSTULE; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; RELIABILITY; SAMPLE SIZE; SKIN MANIFESTATION; STEADY STATE; VOMITING;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; ANALGESICS, OPIOID; DRUG DELIVERY SYSTEMS; FEMALE; FENTANYL; HUMANS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; THERAPEUTIC EQUIVALENCY;

EID: 29144442167     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X65259     Document Type: Article

References (18)

1. Jeal W, Benfield P. Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control. Drugs 53(1):109-38
2. Allan L, Hays H, Jensen NH, et al. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. Br Med J 2001;322(7295):1154-8
3. Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life [The TTS-Fentanyl Comparative Trial Group]. J Pain Symptom Manage 1997;13(5):254-61
4. Clark AJ, Ahmedzai SH, Allan LG, et al. Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain. Curr Med Res Opin 2004;20(9):1419-28
5. rd World Congress of the World Institute of Pain, Barcelona, Spain, September, 2004. In: Devor M et al., editors. Pain practice. Blackwell Publishing; 2004. p. 288-9
6. Mehdizadeh A, Toliate T, Rouini MR, Abashzadeh S, Dorkoosh F. Design and in vitro evaluation of new drug-in-adhesive formulations of fentanyl transdermal patches. Acta Pharm 2004;54(4):301-17
7. rd World Congress of the World Institute of Pain, Barcelona, Spain, September, 2004. In: Devor M, Erdine S, Ruiz-Lopez R, editors. Book of abstracts 3rd World Congress World Institute of Pain, September 21-25, 2004, Barcelona, Spain. Pain practice, p. 288-9
8. MLIC. Metropolitan height and weight tables. Stats Bull Met Life Insurance Company 1983;64:2-9
9. Anderson LS, Grafelman DD, Carnes EJ, Sartwell CJ, Andaloro VJ, Lin PP. Development and validation of an exceptionally sensitive LC-MS/MS method to analyze fentanyl and naltrexone in human serum. AAPS PharmSci 2002;4 (4): [abstract W5207]
10. Portenoy RK, Southam MA, Gupta SK, et al. Transdermal fentanyl for cancer pain. Repeated dose pharmacokinetics. Anesthesiology 1993;78(1):36-43
11. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987;15(6):657-80
12. Chow S, Liu J. Statistical methods for average bioavailability. In: Design and analysis of bioavailability and bioequivalence studies. New York: Marcel Dekker; 1992. p. 70-125
13. FDA. Guidance for industry: statistical approaches to establishing bioequivalence. Rockville (MD): US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research; 2001
14. rd World Congress of the World Institute of Pain, Barcelona, Spain, September, 2004. In: Devor M, Erdine S, Ruiz-Lopez R, editors. Book of abstracts 3rd World Congress World Institute of Pain, September 21-25, 2004, Barcelona, Spain. Pain practice, p. 288-9
15. CPMP. Note for guidance on modified release oral and transdermal dosage forms: section II (pharmacokinetic and clinical evaluation). London: European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products; 1999
16. Grond S, Radbruch L, Lehmann KA. Clinical pharmacokinetics of transdermal opioids: focus on transdermal fentanyl. Clin Pharmacokinet 2000;38(1):59-89
17. rd World Congress of the World Institute of Pain, Barcelona, Spain, September, 2004. In: Devor M, Erdine S, Ruiz-Lopez R, editors. Book of abstracts 3rd World Congress World Institute of Pain, September 21-25, 2004, Barcelona, Spain. Pain practice, p. 288-9
18. Esteve M, Levron JC, Flaisler B, Schoefler P, Duvaldestin P, Chauvin M. Does aging modify pharmacokinetics of transdermal fentanyl? Anesthesiology 1991;75:A705